Upstate Active Clinical Trials
Study Title:RU051417I - Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-
Etoposide) and Lenalidomide-R-ICE (R2-ICE) in Patients with First-Relapse/Primary Refractory Diffuse
Large B-Cell Lymphoma (DLBCL)
What is the purpose of the study?The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (R-ICE) has on you and your cancer. The combination of Lenalidomide with standard chemotherapy is also referred to as R2-ICE.
Upstate Institutional Review Board (IRB) Number:840308
Study Phase:Phase II
Patient Age Group:Adults
Principal Investigator:Teresa C Gentile, MD, PhD
What is involved if I participate?
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
Where will the study take place?Upstate Hospital
Who can I contact for more information?
Name: Corey Chase